SELLAS Life Sciences Group, Inc. operates as a biopharmaceutical company. The Company develops late-stage oncology drugs and therapies for the treatment of cancer diseases. SELLAS Life Sciences Group serves patients worldwide.

Current Report (Form 8-K | Period ending 2025-11-12)

Quarterly Report (Form 10-Q | Period ending 2025-09-30)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

SELLAS Life Sciences Group (SLS US)

Current Report (Form 8-K | Period ending 2025-11-12)

Quarterly Report (Form 10-Q | Period ending 2025-09-30)

424B5 | Prospectus

Current Report (Form 8-K | Period ending 2025-10-24)

S-3 | Registration statement for specified transactions by certain issuers

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)